FDAnews
www.fdanews.com/articles/178535-semaglutide-decreases-cardiovascular-risks-in-phase-iii-diabetes-trial

Semaglutide Decreases Cardiovascular Risks in Phase III Diabetes Trial

September 21, 2016

Semaglutide significantly reduced the risk of first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke by 26 percent, compared to placebo, when added to standard of care of patients with type 2 diabetes at high risk for cardiovascular disease in a Phase III trial.

There was a significant 39 percent decrease in non-fatal stroke, a non-significant 26 percent decrease in non-fatal myocardial infarction, and a neutral 2 percent decrease in CV death after two years of treatment. The trial enrolled 3,297 adults with type 2 diabetes, and based its results on an accumulation of first major adverse CV events in 254 people.

Also, fewer serious adverse events were seen with semaglutide compared to placebo; however, treatment discontinuation due to adverse events was more frequent with semaglutide, mainly due to gastrointestinal events. The results were presented at the annual meeting of the European Association for the Study of Diabetes and were published in the New England Journal of Medicine.

View today's stories